Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)
Ramalingam, S. S. Ahn, M. J. Akamatsu, H. Borghaei, H. Hummel, H. D. Johnson, M. L. Reck, M. Zhang, Y. Jandial, D.
Ramalingam, S. S.
Ahn, M. J.
Akamatsu, H.
Borghaei, H.
Hummel, H. D.
Johnson, M. L.
Reck, M.
Zhang, Y.
Jandial, D.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall FH, Borghaei H, Hummel HD, et al. Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305117.